388 related articles for article (PubMed ID: 28166537)
1. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.
Zhao D; Lu X; Wang G; Lan Z; Liao W; Li J; Liang X; Chen JR; Shah S; Shang X; Tang M; Deng P; Dey P; Chakravarti D; Chen P; Spring DJ; Navone NM; Troncoso P; Zhang J; Wang YA; DePinho RA
Nature; 2017 Feb; 542(7642):484-488. PubMed ID: 28166537
[TBL] [Abstract][Full Text] [Related]
2. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.
Augello MA; Liu D; Deonarine LD; Robinson BD; Huang D; Stelloo S; Blattner M; Doane AS; Wong EWP; Chen Y; Rubin MA; Beltran H; Elemento O; Bergman AM; Zwart W; Sboner A; Dephoure N; Barbieri CE
Cancer Cell; 2019 Apr; 35(4):603-617.e8. PubMed ID: 30930119
[TBL] [Abstract][Full Text] [Related]
3. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.
Zhao D; Cai L; Lu X; Liang X; Li J; Chen P; Ittmann M; Shang X; Jiang S; Li H; Meng C; Flores I; Song JH; Horner JW; Lan Z; Wu CJ; Li J; Chang Q; Chen KC; Wang G; Deng P; Spring DJ; Wang YA; DePinho RA
Cancer Discov; 2020 Sep; 10(9):1374-1387. PubMed ID: 32385075
[TBL] [Abstract][Full Text] [Related]
4. Organ-specific regulation of CHD1 by acute PTEN and p53 loss in mice.
Rahmy S; Cheng X; Wang M; Feng H; Qiu W; Zhao R; Lu X
Biochem Biophys Res Commun; 2020 May; 525(3):614-619. PubMed ID: 32115152
[TBL] [Abstract][Full Text] [Related]
5. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
6. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
Tang YC; Ho SC; Tan E; Ng AWT; McPherson JR; Goh GYL; Teh BT; Bard F; Rozen SG
Breast Cancer Res; 2018 Mar; 20(1):22. PubMed ID: 29566768
[TBL] [Abstract][Full Text] [Related]
7. Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.
Kari V; Mansour WY; Raul SK; Baumgart SJ; Mund A; Grade M; Sirma H; Simon R; Will H; Dobbelstein M; Dikomey E; Johnsen SA
EMBO Rep; 2016 Nov; 17(11):1609-1623. PubMed ID: 27596623
[TBL] [Abstract][Full Text] [Related]
8. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells.
Kikuno N; Shiina H; Urakami S; Kawamoto K; Hirata H; Tanaka Y; Majid S; Igawa M; Dahiya R
Int J Cancer; 2008 Aug; 123(3):552-60. PubMed ID: 18431742
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer.
Liu W; Lindberg J; Sui G; Luo J; Egevad L; Li T; Xie C; Wan M; Kim ST; Wang Z; Turner AR; Zhang Z; Feng J; Yan Y; Sun J; Bova GS; Ewing CM; Yan G; Gielzak M; Cramer SD; Vessella RL; Zheng SL; Grönberg H; Isaacs WB; Xu J
Oncogene; 2012 Aug; 31(35):3939-48. PubMed ID: 22139082
[TBL] [Abstract][Full Text] [Related]
10. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.
Burkhardt L; Fuchs S; Krohn A; Masser S; Mader M; Kluth M; Bachmann F; Huland H; Steuber T; Graefen M; Schlomm T; Minner S; Sauter G; Sirma H; Simon R
Cancer Res; 2013 May; 73(9):2795-805. PubMed ID: 23492366
[TBL] [Abstract][Full Text] [Related]
11. Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.
Chatterjee N; Pazarentzos E; Mayekar MK; Gui P; Allegakoen DV; Hrustanovic G; Olivas V; Lin L; Verschueren E; Johnson JR; Hofree M; Yan JJ; Newton BW; Dollen JV; Earnshaw CH; Flanagan J; Chan E; Asthana S; Ideker T; Wu W; Suzuki J; Barad BA; Kirichok Y; Fraser JS; Weiss WA; Krogan NJ; Tulpule A; Sabnis AJ; Bivona TG
Cell Rep; 2019 Aug; 28(9):2317-2330.e8. PubMed ID: 31461649
[TBL] [Abstract][Full Text] [Related]
12. Human CHD1 is required for early DNA-damage signaling and is uniquely regulated by its N terminus.
Zhou J; Li J; Serafim RB; Ketchum S; Ferreira CG; Liu JC; Coe KA; Price BD; Yusufzai T
Nucleic Acids Res; 2018 May; 46(8):3891-3905. PubMed ID: 29529298
[TBL] [Abstract][Full Text] [Related]
13. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
14. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer.
Ding Y; Li N; Dong B; Guo W; Wei H; Chen Q; Yuan H; Han Y; Chang H; Kan S; Wang X; Pan Q; Wu P; Peng C; Qiu T; Li Q; Gao D; Xue W; Qin J
J Clin Invest; 2019 Feb; 129(2):759-773. PubMed ID: 30496141
[TBL] [Abstract][Full Text] [Related]
15. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness.
Huang S; Gulzar ZG; Salari K; Lapointe J; Brooks JD; Pollack JR
Oncogene; 2012 Sep; 31(37):4164-70. PubMed ID: 22179824
[TBL] [Abstract][Full Text] [Related]
16. Dual degradation signals destruct GLI1: AMPK inhibits GLI1 through β-TrCP-mediated proteasome degradation.
Zhang R; Huang SY; Ka-Wai Li K; Li YH; Hsu WH; Zhang GJ; Chang CJ; Yang JY
Oncotarget; 2017 Jul; 8(30):49869-49881. PubMed ID: 28562331
[TBL] [Abstract][Full Text] [Related]
17. Human RNA polymerase II-association factor 1 (hPaf1/PD2) regulates histone methylation and chromatin remodeling in pancreatic cancer.
Dey P; Ponnusamy MP; Deb S; Batra SK
PLoS One; 2011; 6(10):e26926. PubMed ID: 22046413
[TBL] [Abstract][Full Text] [Related]
18. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
Boysen G; Rodrigues DN; Rescigno P; Seed G; Dolling D; Riisnaes R; Crespo M; Zafeiriou Z; Sumanasuriya S; Bianchini D; Hunt J; Moloney D; Perez-Lopez R; Tunariu N; Miranda S; Figueiredo I; Ferreira A; Christova R; Gil V; Aziz S; Bertan C; de Oliveira FM; Atkin M; Clarke M; Goodall J; Sharp A; MacDonald T; Rubin MA; Yuan W; Barbieri CE; Carreira S; Mateo J; de Bono JS
Clin Cancer Res; 2018 Nov; 24(22):5585-5593. PubMed ID: 30068710
[No Abstract] [Full Text] [Related]
19. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
[TBL] [Abstract][Full Text] [Related]
20. BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer.
M JR; S V
Gene; 2018 Dec; 678():302-311. PubMed ID: 30096458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
